TrialJAMA neurology2020

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

James F Howard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.